Evidence map›Paper›PMID 34503975›Full record

ArticleMolecular pharmacology2021

Characterization of VU0468554, a New Selective Inhibitor of Cardiac G Protein-Gated Inwardly Rectifying K

Allison Anderson, Baovi N Vo, Ezequiel Marron Fernandez de Velasco, Corey R Hopkins, C David Weaver, Kevin Wickman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Relevance ofInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Allison AndersonGraduate Program in Pharmacology (A.A., B.N.V.) and Department of Pharmacology (E.M.F.d.V., K.W.), University of Minnesota, Minneapolis, Minnesota; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.); and Departments of Pharmacology and Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (C.D.W.).
Baovi N VoGraduate Program in Pharmacology (A.A., B.N.V.) and Department of Pharmacology (E.M.F.d.V., K.W.), University of Minnesota, Minneapolis, Minnesota; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.); and Departments of Pharmacology and Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (C.D.W.).
Ezequiel Marron Fernandez de VelascoGraduate Program in Pharmacology (A.A., B.N.V.) and Department of Pharmacology (E.M.F.d.V., K.W.), University of Minnesota, Minneapolis, Minnesota; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.); and Departments of Pharmacology and Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (C.D.W.).
Corey R HopkinsGraduate Program in Pharmacology (A.A., B.N.V.) and Department of Pharmacology (E.M.F.d.V., K.W.), University of Minnesota, Minneapolis, Minnesota; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.); and Departments of Pharmacology and Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (C.D.W.).
C David WeaverGraduate Program in Pharmacology (A.A., B.N.V.) and Department of Pharmacology (E.M.F.d.V., K.W.), University of Minnesota, Minneapolis, Minnesota; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.); and Departments of Pharmacology and Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (C.D.W.).
Kevin WickmanGraduate Program in Pharmacology (A.A., B.N.V.) and Department of Pharmacology (E.M.F.d.V., K.W.), University of Minnesota, Minneapolis, Minnesota; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.); and Departments of Pharmacology and Chemistry and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (C.D.W.) wickm002@umn.edu.
University of Minnesota · USUniversity of Nebraska Medical Center · USVanderbilt University · US

Funding

Relevance and plasticity of inhibitory metabotropic signaling in reward circuitsR01DA034696 · NIDA · UNIVERSITY OF MINNESOTA · PI WICKMAN, KEVIN D · 2013 to 2022
$3.4M
The role of RGS proteins in the parasympathetic control of heart rateR01HL105550 · NHLBI · UNIVERSITY OF MINNESOTA · PI MARTEMYANOV, KIRILL A., WICKMAN, KEVIN D · 2011 to 2018
$3.2M
Alcohol-related suppression of GIRK channel activity in the basal amygdala: a link to plasticity of glutamatergic neurotransmission and withdrawal-associated behavior?R01AA027544 · NIAAA · UNIVERSITY OF MINNESOTA · PI WICKMAN, KEVIN D · 2020 to 2024
$1.7M
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel ActivatorR01MH107399 · NIMH · VANDERBILT UNIVERSITY · PI HOPKINS, COREY R., WEAVER, C DAVID · 2015 to 2017
$1.6M
Targeting the parasympathetic regulation of the heart to treat arrhythmiasF31HL139090 · NHLBI · UNIVERSITY OF MINNESOTA · PI ANDERSON, ALLISON DIANE · 2017 to 2019
$120k
NHLBI NIH HHS F31 HL139090NHLBI NIH HHS R01 HL105550NIAAA NIH HHS R01 AA027544NIDA NIH HHS R01 DA034696NIMH NIH HHS R01 MH107399
6 · The paper itself

Abstract

G protein-gated inwardly rectifying K

Indexed as

Action PotentialsAnimalsFemaleG Protein-Coupled Inwardly-Rectifying Potassium ChannelsHEK293 CellsHippocampusHumansMaleMiceMice, Inbred C57BLMyocytes, CardiacNeuronsPotassium Channel BlockersG Protein-Coupled Inwardly-Rectifying Potassium ChannelsPotassium Channel Blockers

Identifiers

PMID34503975
PMCPMC8626782
OpenAlexW3197179229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.